Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA

被引:51
作者
Choi, M
Rolle, S
Rane, M
Haller, H
Luft, FC
Kettritz, R
机构
[1] Humboldt Univ, Charite, Fac Med, Max Delbruck Ctr Mol Med, Berlin, Germany
[2] Humboldt Univ, HELIOS Klinkum Berlin Franz Volhard Clin, Berlin, Germany
[3] Univ Louisville, Mol Lab, Louisville, KY 40292 USA
[4] Hannover Med Sch, Dept Nephrol, D-3000 Hannover, Germany
关键词
neutrophils; anti-neutrophil cytoplasmic antibodies; 3-hydroxy-3-methylglutaryl coenzyme A; superoxide; signal transduction; mitogen-activated protein kinases; respiratory burst;
D O I
10.1046/j.1523-1755.2003.00718.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) may modulate cellular inflammatory functions independent of serum cholesterol. We tested the hypothesis that statins decrease respiratory burst activity of human polymorphonuclear neutrophils (PMN) in response to anti-neutrophil cytoplasmic antibodies (ANCA). Methods. Neutrophils were isolated from healthy human volunteers, human immunoglobulins were isolated from patients with proteinase-3 (PR3)- and myeloperoxidase (MPO)-ANCA. Superoxide generation was measured by the ferricytochrome C assay and the nitro blue tetrazolium (NBT) test. ANCA antigen expression was measured by flow cytometry and phosphorylation of mitogen-activated protein kinase (MAPK) was assessed by Western blotting. Results. Cerivastatin and simvastatin inhibited respiratory burst activity to ANCA dose-dependently (1 to 25 mumol/L). Tumor necrosis factor-alpha (TNF-alpha)-primed neutrophils released 26.7 +/- 2.8 nmol O-2 (-) /0.75 x 10(6) PMN/45 min and 10 mumol/L simvastatin reduced this amount to 18.0 +/- 2.1 nmol. The inhibitory effect was confirmed by the NBT test. The respiratory burst decrease could not be reversed by 500 mumol/L mevalonic acid (MVA). In this assay, both statins also inhibited the response to human ANCA. PR3-ANCA resulted in 19.4 +/- 2.0 nmol O-2 (-) nmol. This amount was decreased to 6.0 +/- 1.2 nmol by preincubation with 10 mumol/L simvastatin (P < 0.01). For MPO-ANCA, the values were 22.6 +/- 2.8 nmol for controls versus 16.7 +/- 3.1 nmol with statin (P < 0.01). By FACS, simvastatin decreased TNF-alpha-mediated ANCA antigen translocation (from 219 +/- 33 to 180 +/- 35 MFI for PR3 and 24.0 +/- 2.4 to 18.3 +/- 1.1 for MPO). Finally, since p38 MAPK and ERK control TNF-alpha priming, we studied the effects of both statins on MAPK. Western blotting showed that statins inhibited TNF-alpha-induced ERK phosphorylation in a dose dependent fashion, but had no effect on p38. Conclusion. These findings demonstrate that HMG-CoA reductase inhibitors decrease respiratory burst activity of human PMN in response to ANCA. This effect was independent of mevalonate, but involved inhibition of ERK activation during TNF-alpha priming. Our data suggest that HMG-CoA reductase inhibitors may help limit inflammatory responses.
引用
收藏
页码:96 / 106
页数:11
相关论文
共 36 条
  • [11] Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells
    Hernández-Perera, O
    Pérez-Sala, D
    Soria, E
    Lamas, S
    [J]. CIRCULATION RESEARCH, 2000, 87 (07) : 616 - 622
  • [12] Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease
    Horne, BD
    Muhlestein, JB
    Carlquist, JF
    Bair, TL
    Madsen, TE
    Hart, NI
    Anderson, JL
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (06) : 1774 - 1780
  • [13] Ikeda U, 1999, LANCET, V353, P1274, DOI 10.1016/S0140-6736(05)75195-3
  • [14] Small-vessel vasculitis
    Jennette, JC
    Falk, RJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (21) : 1512 - 1523
  • [15] KALLENBERG CGM, 1995, CLIN EXP IMMUNOL, V100, P1
  • [16] Selective inhibition of formyl-methionyl-leucyl- phenylalanine (fMLF)-dependent superoxide generation in neutrophils by pravastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
    Kanno, T
    Abe, K
    Yabuki, M
    Akiyama, J
    Yasuda, T
    Horton, AA
    [J]. BIOCHEMICAL PHARMACOLOGY, 1999, 58 (12) : 1975 - 1980
  • [17] Kettritz R, 2001, J AM SOC NEPHROL, V12, P37, DOI 10.1681/ASN.V12137
  • [18] Kettritz R, 1997, J AM SOC NEPHROL, V8, P386
  • [19] TISSUE SELECTIVITY OF PRAVASTATIN SODIUM, LOVASTATIN AND SIMVASTATIN - THE RELATIONSHIP BETWEEN INHIBITION OF DENOVO STEROL SYNTHESIS AND ACTIVE-DRUG CONCENTRATIONS IN THE LIVER, SPLEEN AND TESTIS IN RAT
    KOGA, T
    FUKUDA, K
    SHIMADA, Y
    FUKAMI, M
    KOIKE, H
    TSUJITA, Y
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1992, 209 (01): : 315 - 319
  • [20] Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae
    Kothe, H
    Dalhoff, K
    Rupp, J
    Müller, A
    Kreuzer, J
    Maass, M
    Katus, HA
    [J]. CIRCULATION, 2000, 101 (15) : 1760 - 1763